ProfileGDS5678 / 1447812_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 51% 58% 57% 54% 58% 57% 62% 59% 64% 59% 60% 54% 57% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2713951
GSM967853U87-EV human glioblastoma xenograft - Control 23.5108258
GSM967854U87-EV human glioblastoma xenograft - Control 33.463157
GSM967855U87-EV human glioblastoma xenograft - Control 43.2835854
GSM967856U87-EV human glioblastoma xenograft - Control 53.4378958
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5617157
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8040762
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5617959
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8274664
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5412859
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6093160
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2981454
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4569257
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3880755